John DeFord Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John DeFord NUVA stock SEC Form 4 insiders trading

John has made over 6 trades of the Nuvasive Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 14,107 units of NUVA stock worth 2,451,091$ on 20 December 2017.

The largest trade he's ever made was exercising 14,107 units of Nuvasive Inc stock on 20 December 2017 worth over 2,451,091$. On average, John trades about 1,213 units every 33 days since 2014. As of 20 December 2017 he still owns at least 30,896 units of Nuvasive Inc stock.

You can see the complete history of John Ford stock trades at the bottom of the page.

John DeFord biography

Dr. John A. DeFord Ph.D. serves as Independent Director of the Company. Dr. DeFord is currently the Executive Vice President and Chief Technology Officer for Becton, Dickinson and Company, a global medical technology company. Dr. DeFord previously served as the Senior Vice President, Research and Development, Interventional Segment for Becton Dickinson from December 2017 to June 2018 following its acquisition of C.R. Bard, Inc., where he had served as Senior Vice President, Science, Technology and Clinical Affairs since June 2007. Dr. DeFord joined Bard in 2004, and served in science and technology roles of increasing responsibility since that time. Prior to joining Bard, Dr. DeFord was Managing Director of Early Stage Partners LP, a venture capital fund. Prior to joining Early Stage Partners, Dr. DeFord was President and CEO of Cook Incorporated, a privately held medical device manufacturer. Dr. DeFord brings to our Board valuable strategy, technology development and clinical affairs leadership experience within the medical device industry.

What is the salary of John DeFord?

As the Independent Director of Nuvasive Inc, the total compensation of John DeFord at Nuvasive Inc is 230,057$. There are 11 executives at Nuvasive Inc getting paid more, with J. Christopher Barry having the highest compensation of 5,425,440$.

How old is John DeFord?

John DeFord is 58, he's been the Independent Director of Nuvasive Inc since 2018. There are 3 older and 15 younger executives at Nuvasive Inc. The oldest executive at Nuvasive Inc is Donald Rosenberg, 69, who is the Independent Director.

What's John DeFord's mailing address?

John's mailing address filed with the SEC is 28601, Clemens Road, Westlake, Cuyahoga County, Ohio, 44145, United States.

Insiders trading at Nuvasive Inc

Over the last 21 years, insiders at Nuvasive Inc have traded over 60,917,905$ worth of Nuvasive Inc stock and bought 185,079 units worth 8,372,956$ . The most active insiders traders include Jesse I Treu、James C Blair、Brian H Dovey. On average, Nuvasive Inc executives and independent directors trade stock every 11 days with the average trade being worth of 415,308$. The most recent stock trade was executed by Marc W. Rosenbaum on 1 March 2023, trading 1,829 units of NUVA stock currently worth 72,703$.

What does Nuvasive Inc do?

nuvasive® is a place where we create new and innovative products at a speed that drives our ability to deliver absolute responsiveness®, and gives us a competitive edge. at nuvasive, we empower our shareowners to influence results and significantly contribute to the success of the company. together we make nuvasive a leader in the spine industry with our unique focus on speed of innovation®. every member of the nuvasive family has the opportunity to improve the lives of patients through their work. these life-changing career paths show how hard work, a competitive spirit and your unwavering dedication to the patient can take you and your career to new places. in addition to being a great place to have a career, we’re also committed to giving back and supporting our communities. through an attitude of gratitude, nuvasive provides life-changing spinal surgery to disadvantaged communities through our nonprofit, the nuvasive spine foundation®, and offers patient-to-patient support through

Nuvasive Inc executives and stock owners

Nuvasive Inc executives and other stock owners filed with the SEC include:

• J. Christopher Barry,
  Chief Executive Officer, Director
• J. Christopher Barry,
  CEO & Director
• Nathaniel Sisitsky,
  Senior Vice President, General Counsel, Corporate Secretary
• Matthew K. Harbaugh,
  Exec. VP & CFO
• Gregory Lucier,
  Chairman of the Board
• Nathaniel B. Sisitsky Esq.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Lucas Vitale,
  Sr. VP & Chief HR Officer
• Donald Rosenberg,
  Independent Director
• Daniel Wolterman,
  Independent Director
• Vickie Capps,
  Independent Director
• Leslie Norwalk,
  Independent Director
• R. Scott Huennekens,
  Independent Director
• Robert Friel,
  Independent Director
• John DeFord,
  Independent Director
• Suzanne Hatcher,
  Vice President, Internal & External Affairs
• Dale Wolf,
  Senior Vice President - Global Operations
• Massimo Calafiore,
  Executive Vice President - Global Business Units
• Brent Boucher,
  Executive Vice President - Global Commercial
• Lucas Vitale,
  Chief Human Resource Officer
• Matthew Harbaugh,
  Executive Vice President, Chief Financial Officer
• Marc Rosenbaum,
  VP, Corp. Controller & Chief Accounting Officer
• Michael Farrington,
  VP of Corp. Marketing, Brand & Communication
• Juliet C. Cunningham,
  VP of Investor Relations
• Ryan Donahoe,
  Chief Technology Officer
• Dale A. Wolf,
  Sr. VP of Global Operations
• Lisa Pecora,
  VP & Head of Global Commercial Fin.
• Frank Middeke,
  Managing Director of DACH
• Sean Freeman,
  Sr. VP of Strategy & Corp. Devel.
• Johnson Lai,
  Chief Information Officer
• Jereme M Sylvain,
  Chief Accounting Officer
• Jack R Blair,
  Director
• Peter Michael Leddy,
  Director
• Edmund J Roschak,
  CEO, NuVasive Spec. Orthopedic
• Dan Wolterman,
  Director
• Michael D Ohalleran,
  Director
• Lesley H Howe,
  Director
• Peter C Farrell,
  Director
• Joan Stafslien,
  EVP and General Counsel
• Quentin S. Blackford,
  CFO and CAO
• Cox Carol,
  EVP Strategy, Corp Dev
• Tyler Lipschultz,
  EVP, Biologics
• Andrew C. Morton,
  SVP, CHRO
• Matthew Link,
  President
• Rajesh Asarpota,
  CFO
• Paul Mc Clintock,
  President, U.S. Commercial
• Stephen Rozow,
  EVP, Global Process
• Jeffrey P Rydin,
  Senior V.P., U.S. Sales
• Jason Hannon,
  VP, Legal Affairs & Secretary
• Patrick Miles,
  Senior VP, Marketing
• Kevin C Oboyle,
  CFO and Executive VP
• James C Blair,
  Director
• James J Skinner,
  VP,Strategic Sales Development
• Jonathan Spangler,
  VP & Chief Patent Counsel
• G Bryan Cornwall,
  VP, Research & Development
• Hansen A Yuan,
  Director
• Arda Minocherhomjee,
  Director
• Blair Capital Management Vi...,
  
• Perkins Caufield & Byers Vi...,
  10% owner
• Joseph Lacob,
  Director
• G Rogan Fry,
  Sr. V. P., Corp. Development
• Viii Associates Lp Kpcb,
  10% owner
• Life Sciences Zaibatsu Fund...,
  10% owner
• Iv Associates Lp Dp,
  10% owner
• Jesse I Treu,
  10% owner
• Kathleen K Schoemaker,
  10% owner
• Brian H Dovey,
  10% owner
• Vii Associates Lp Kpcb,
  10% owner
• De Depot Et Placement Du Qu...,
  10% owner
• Management Partners Iv Lpen...,
  
• Partners Iv Lp Domain,
  10% owner
• Viii Founders Fund L P Kpcb,
  10% owner
• Russell Powers,
  Exec. VP Sales Int'l Ops
• Eileen M More,
  Director
• Keith Valentine,
  President
• Alexis V Lukianov,
  CEO and Chairman
• Michael E Paolucci,
  Exec. V.P., Global HR
• Craig E Hunsaker,
  SVP, Global Human Resources
• Richard Iii Treharne,
  Director
• Michael Lambert,
  CFO and Executive VP
• Robert J Hunt,
  Director
• Siddhartha Kadia,
  Director
• Amy Belt Raimundo,
  Director
• Michael Farrington,
  SVP, People and Culture
• Marc W. Rosenbaum,
  Chief Accounting Officer